Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

Asan Medical Center

Status and phase: Completed; Phase 2

Conditions: Metastatic Colorectal Cancer

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT00378066

AMC-ONCGI-0277

Details and patient eligibility

About

The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.

Enrollment: 49 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically documented colorectal adenocarcinoma
• ECOG performance status of 2 or lower
• Adequate bone marrow function
• Adequate kidney function
• Adequate liver function
• Informed consent

Exclusion criteria

• Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start
• Known allergy to study drugs

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

49 participants in 1 patient group

Bevacizumab

Active Comparator group

Description:

Bevacizumab, capecitabine and oxaliplatin for metastatic colorectal cancer, 1st line treatment

Treatment:

Drug: Bevacizumab